Trial Profile

Bioequivalence Study of Bixalomer (AMG 223, ASP1585) Granule in Chronic Kidney Disease Patients with Hyperphosphataemia on Dialysis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bixalomer (Primary)
Indications Hyperphosphataemia
Focus Pharmacokinetics
Sponsors Astellas Pharma

Most Recent Events

30 May 2014 New trial record
12 May 2014 According to Astellas Pharma product pipeline list announced in May 2014, a bioequivalence study of a new formulation of bixalomer has been initiated in Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com